Amit Patel, DO
Cardiovascular Disease · Houston, TXNPI 1467895078
Payments from drug & device makers
Across 164 payments — averaging $50.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Abiomed$1K
- Boston Scientific$468
- Edwards Lifesciences$344
- Medtronic$310
- Novartis$300
- plus $2K from 28 others
What the payments were for
- Travel & lodging$2,58231%
- Food & beverage$5,51367%
- Education$1051%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 35 | $3,743 |
| Abiomed | 9 | $1,005 |
| Boston Scientific | 14 | $468 |
| Edwards Lifesciences | 6 | $344 |
| Medtronic(2 entities) | 4 | $310 |
| Novartis | 12 | $300 |
| Merck | 15 | $257 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $228 |
| Amgen | 10 | $185 |
| Novo Nordisk | 2 | $149 |
| AstraZeneca | 3 | $147 |
| Irhythm Technologies, Inc. | 8 | $144 |
| Janssen Scientific Affairs, LLC | 1 | $133 |
| E.r. Squibb & Sons, L.L.C. | 6 | $120 |
| Pfizer | 6 | $111 |
| Cardiva Medical, Inc. | 3 | $77 |
| Artivion, Inc. | 1 | $64 |
| Azurity Pharmaceuticals, Inc. | 2 | $43 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $40 |
| Altathera Pharmaceuticals LLC | 1 | $38 |
| Cvrx, Inc. | 2 | $29 |
| Impulse Dynamics (USA) Inc. | 1 | $28 |
| W. L. Gore & Associates, Inc. | 1 | $27 |
| Atricure, Inc. | 1 | $26 |
| Johnson & Johnson | 2 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $22 |
| Sensible Medical Innovations Inc | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Angiodynamics, Inc. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Baylis Medical Company Inc | 1 | $13 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$1,124
- Ensite Cardiac Mapping System$1,110
- Impella$768
- COREVALVE EVOLUT R$168
- iLab Ultrasound Imaging System$137
- XARELTO$133
- FARXIGA$118
How this compares
$8,200 in reported general payments places this provider in the 65th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 317 | $382,498 |
| XareltoRivaroxaban | 163 | $190,295 |
| EntrestoSacubitril/Valsartan | 108 | $134,499 |
| FarxigaDapagliflozin Propanediol | 41 | $53,925 |
| JardianceEmpagliflozin | 31 | $41,577 |
| VascepaIcosapent Ethyl | 24 | $12,795 |
| Praluent PenAlirocumab | 14 | $10,815 |
| Repatha SureclickEvolocumab | 11 | $9,007 |
| BrilintaTicagrelor | 12 | $8,743 |
| Metoprolol Succinate | 442 | $6,692 |
| Rosuvastatin Calcium | 354 | $4,896 |
| Atorvastatin Calcium | 480 | $4,421 |
| Ezetimibe | 158 | $4,379 |
| Flecainide Acetate | 88 | $4,338 |
| Losartan Potassium | 230 | $2,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $111 | $382,498317 claims |
| Johnson & JohnsonXarelto | $22 | $190,295163 claims |
| NovartisEntresto | $300 | $134,499108 claims |
| AstraZenecaFarxiga, Brilinta | $147 | $62,66753 claims |
| Boehringer IngelheimJardiance | $20 | $41,57731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- James FeldmanHouston$3.1M
- Aditya SamalHouston$2.6M
- Pranav LoyalkaHouston$2.4M
- Anwar AhmadHouston$1.4M
- Reynolds DelgadoHouston$1.1M
- Richard SmallingHouston$908K
- Amin KarimHouston$853K
- Stephen LittleHouston$806K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.